Skip to content
Dosage GuideResearch Reference

KPV Dosage

Research-based dosing protocols, timing guidance, and reconstitution reference for KPV. All information is for educational purposes only.

Quick Answer

KPV is typically administered at 1–3 mg per dose orally or 0.5 - 1 mg via subcutaneous injection once or twice daily in preclinical studies. Oral administration is common due to ease of use, but bioavailability may be lower than injection. No human clinical dose-ranging trials have been completed.

→ KPV Benefits→ KPV Side Effects→ Full KPV Profile
Table of Contents

Standard Dosage Range

Research dosing range: 1–3 mg per dose (oral); 0.5-1 mg (injection)

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

Inflammatory Bowel Disease (IBD) / Colitis

1–3 mg1–2× daily
Duration

4–8 weeks

Oral administration (capsule) is preferred. Some studies used enema administration to target the colon directly. Monitor symptoms and adjust dose as needed.

Gut Barrier Repair / Leaky Gut

1–2 mg1× daily
Duration

4–6 weeks

Oral administration (capsule) is preferred. Consider combining with other gut-healing supplements like L-glutamine and zinc carnosine.

Skin Inflammation (Dermatitis / Eczema)

0.5-1 mg1× daily
Duration

4–8 weeks

Subcutaneous injection or topical application (compounded cream). Some protocols use both oral and topical administration for synergistic effects.

Systemic Anti-Inflammatory

1 mg1× daily
Duration

4–8 weeks

Oral or subcutaneous administration. Lower dose for systemic use. Not yet validated in human trials.

Timing & Frequency

For IBD and gut health, oral dosing is typically administered 30 minutes before meals. For skin inflammation, injections are often administered in the evening. KPV has a very short half-life (~minutes in plasma), but it is thought to act intracellularly so frequent dosing may not be necessary.

Cycle Guidance

Most preclinical studies ran 4–8 week protocols. Common research practice uses a 6–8 week cycle followed by a 4-week break. KPV does not appear to suppress endogenous systems, so cycling rationale is primarily precautionary given limited long-term human safety data.

Reconstitution Reference

Quick reference for reconstituting KPV. For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial SizeTypically 10 mg per vial
BAC Water Volume5 mL bacteriostatic water for 2 mg/mL concentration
Concentration & DrawAt 2 mg/mL: 500 mcg = 0.25 mL (25 units on a 100-unit insulin syringe)
StorageRefrigerate at 2–8°C after reconstitution. Keep lyophilized powder at room temperature or refrigerated.
StabilityReconstituted solution stable up to 30 days refrigerated. Lyophilized powder stable 12-24 months per manufacturer specifications.
Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What is the standard KPV dosage for IBD?
Preclinical research typically uses 1–3 mg per dose, administered 1–2 times daily orally for IBD. Human data is lacking.
Can KPV be taken orally?
Yes, KPV is commonly administered orally in preclinical studies. While bioavailability might be less compared to subcutaneous injections, oral administration is generally well-tolerated and convenient.
Are there any known side effects of KPV?
Side effects are generally mild. Injection site reactions, mild GI discomfort, and headaches have been reported. Long-term human safety data is very limited. Consult with a healthcare professional before using KPV.

Last updated: 2026-02-19